D. Boral Capital Reiterates “Buy” Rating for Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals (NASDAQ:RVPH)‘s stock had its “buy” rating reaffirmed by D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $2.00 target price on the stock.

Other analysts have also issued reports about the company. Benchmark cut their price target on Reviva Pharmaceuticals from $14.00 to $7.00 and set a “speculative buy” rating on the stock in a report on Monday, September 15th. Weiss Ratings restated a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a research note on Wednesday, October 8th. Chardan Capital raised shares of Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, November 19th. Wall Street Zen upgraded shares of Reviva Pharmaceuticals to a “sell” rating in a report on Saturday, October 4th. Finally, HC Wainwright reduced their target price on shares of Reviva Pharmaceuticals from $11.00 to $4.00 and set a “buy” rating for the company in a report on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Reviva Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $3.86.

Reviva Pharmaceuticals Stock Down 11.6%

Shares of RVPH stock opened at $0.28 on Tuesday. The firm has a fifty day moving average of $0.56 and a 200-day moving average of $0.52. Reviva Pharmaceuticals has a 12-month low of $0.25 and a 12-month high of $2.17. The company has a market capitalization of $32.68 million, a price-to-earnings ratio of -0.62 and a beta of -0.02.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.05. On average, equities analysts expect that Reviva Pharmaceuticals will post -0.97 EPS for the current year.

Institutional Investors Weigh In On Reviva Pharmaceuticals

Several large investors have recently made changes to their positions in RVPH. Armistice Capital LLC bought a new position in shares of Reviva Pharmaceuticals in the second quarter valued at $1,026,000. 683 Capital Management LLC acquired a new stake in Reviva Pharmaceuticals in the second quarter valued at $381,000. Persistent Asset Partners Ltd grew its position in shares of Reviva Pharmaceuticals by 300.0% in the 2nd quarter. Persistent Asset Partners Ltd now owns 641,174 shares of the company’s stock valued at $244,000 after acquiring an additional 480,864 shares during the period. Millennium Management LLC increased its stake in shares of Reviva Pharmaceuticals by 15.0% during the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock worth $631,000 after purchasing an additional 223,178 shares during the last quarter. Finally, Lido Advisors LLC acquired a new position in shares of Reviva Pharmaceuticals during the 3rd quarter worth about $37,000. Institutional investors and hedge funds own 63.18% of the company’s stock.

Key Headlines Impacting Reviva Pharmaceuticals

Here are the key news stories impacting Reviva Pharmaceuticals this week:

• Positive Sentiment: Analyst bullishness — HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target, implying large upside versus the current price; this bullish call likely fuels speculative interest. Read More.
• Positive Sentiment: Additional buy reiteration — D. Boral Capital maintained a “buy” rating with a $2.00 target, another institutional endorsement that can support upside momentum. Read More.
• Positive Sentiment: Heavy call option buying — traders purchased large volumes of call options (roughly 25,745 calls, ~295% above typical volume), which indicates speculative bullish positioning that can amplify intraday price moves. Read More.
• Neutral Sentiment: Short-interest data flagged as zero/incomplete — reported short interest shows 0 shares (data appears unreliable/NaN change), so it provides no clear signal on short-seller positioning. No meaningful short-squeeze implication from this report.
• Negative Sentiment: Regulatory setback — the FDA recommended a second Phase 3 trial for brilaroxazine in schizophrenia after a pre-NDA meeting, meaning more time, data and cost before potential approval; this is the primary driver of the stock decline. Read More.
• Negative Sentiment: Funding and dilution risk — analysts (Roth) warn Reviva may need an additional $60M–$75M to complete the schizophrenia study, raising dilution and financing concerns that weigh on valuation. Read More.
• Negative Sentiment: Price-target cuts and market reaction — Roth lowered its price target to $1.50 (from $3), and coverage/ headlines note a sharp intraday plunge after the FDA news, reinforcing negative sentiment and selling pressure. Read More. Read More.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.